Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 13/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 13/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22730013 | 1.00 | IDO1 (0.48) | IDO1ESR2TLR7TLR8TLR9 | |
| SCHEMBL22730012 | 1.00 | IDO1 (0.48) | IDO1ESR2TLR7TLR8TLR9 | |
| SCHEMBL9277352 | 0.91 | IDO1 (0.50) | IDO1TLR7TLR8TLR9USP30 | |
| Bicarbonate SCHEMBL9280862 | 0.86 | IDO1 (0.54) | IDO1TLR7TLR8TLR9USP30 | |
| Cyanide SCHEMBL27912025 | 0.85 | IDO1 (0.47) | IDO1TLR7TLR8TLR9USP30 | |
| SCHEMBL12093743 | 0.83 | IDO1 (0.45) | IDO1TLR7TLR8TLR9USP30 | |
| SCHEMBL12093732 | 0.83 | IDO1 (0.45) | IDO1TLR7TLR8TLR9USP30 | |
| SCHEMBL21187181 | 0.82 | IDO1 (0.45) | IDO1TLR7TLR8TLR9USP30 | |
| SCHEMBL30209450 | 0.82 | IDO1 (0.45) | IDO1TLR7TLR8TLR9USP30 | |
| SCHEMBL22402327 | 0.81 | IDO1 (0.44) | IDO1TLR7TLR8TLR9USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110092750-B | Pentafluoro sulfanyl substituted amide compound, preparation method and application thereof in medicine | 北京诺诚健华医药科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-112334458-B | 3-indazolinone compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-20210221808-A1 | 3-OXAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221808-A1 | 3-OXAZOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | IDO1, IDO2, INMT | IDO1 1/4885ESR2 4775/4885TLR7 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.